EBS Emergent BioSolutions Inc.

NYSE emergentbiosolutions.com


$ 13.04 $ 3.44 (36.6 %)    

Thursday, 30-Oct-2025 19:58:11 EDT
QQQ $ 633.20 nm (nm)
DIA $ 475.83 $ -1.36 (-0.29 %)
SPY $ 684.43 nm (nm)
TLT $ 90.42 nm (nm)
GLD $ 371.67 $ 7.13 (1.96 %)
$ 12.84
$ 11.00
$ 12.84 x 266
$ 13.16 x 5
-- - --
$ 4.02 - $ 13.41
8,917,211
na
674.36M
$ 1.69
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 10-29-2025 09-30-2025 10-Q
2 08-06-2025 06-30-2025 10-Q
3 05-07-2025 03-31-2025 10-Q
4 03-03-2025 12-31-2024 10-K
5 11-06-2024 09-30-2024 10-Q
6 08-06-2024 06-30-2024 10-Q
7 05-01-2024 03-31-2024 10-Q
8 03-08-2024 12-31-2023 10-K
9 12-11-2023 09-30-2023 10-Q
10 08-08-2023 06-30-2023 10-Q
11 05-10-2023 03-31-2023 10-Q
12 03-01-2023 12-31-2022 10-K
13 11-09-2022 09-30-2022 10-Q
14 08-01-2022 06-30-2022 10-Q
15 04-28-2022 03-31-2022 10-Q
16 02-25-2022 12-31-2021 10-K
17 11-05-2021 09-30-2021 10-Q
18 07-30-2021 06-30-2021 10-Q
19 04-30-2021 03-31-2021 10-Q
20 02-19-2021 12-31-2020 10-K
21 11-06-2020 09-30-2020 10-Q
22 07-31-2020 06-30-2020 10-Q
23 05-01-2020 03-31-2020 10-Q
24 02-25-2020 12-31-2019 10-K
25 11-07-2019 09-30-2019 10-Q
26 08-02-2019 06-30-2019 10-Q
27 05-08-2019 03-31-2019 10-Q
28 02-22-2019 12-31-2018 10-K
29 11-02-2018 09-30-2018 10-Q
30 08-03-2018 06-30-2018 10-Q
31 05-04-2018 03-31-2018 10-Q
32 02-23-2018 12-31-2017 10-K
33 11-03-2017 09-30-2017 10-Q
34 08-04-2017 06-30-2017 10-Q
35 05-05-2017 03-31-2017 10-Q
36 02-28-2017 12-31-2016 10-K
37 11-09-2016 09-30-2016 10-Q
38 08-05-2016 06-30-2016 10-Q
39 05-06-2016 03-31-2016 10-Q
40 02-29-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-reiterates-buy-on-emergent-biosolutions-maintains-15-price-target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Emergent BioSolutions (NYSE:EBS) with a Buy and maintains $15 ...

 emergent-biosolutions-secures-30m-barda-contract-to-supply-cyfendus-anthrax-vaccine-by-march-2026

Emergent BioSolutions Inc. (NYSE:EBS) today announced it has received a $30 million contract modification from the Biomedical A...

 emergent-biosolutions-files-for-mixed-shelf-of-up-to-250m

 -SEC Filing

 emergent-biosolutions-narrows-fy2025-sales-guidance-from-75000m-85000m-to-76500m-83500m-vs-80000m-est

Emergent BioSolutions (NYSE:EBS) narrows FY2025 sales outlook from $750.00 million-$850.00 million to $765.00 million-$835.00 m...

 emergent-biosolutions-q2-adj-eps-016-beats-072-estimate-sales-14090m-beat-10500m-estimate

Emergent BioSolutions (NYSE:EBS) reported quarterly earnings of $0.16 per share which beat the analyst consensus estimate of $(...

 emergent-biosolutions-publishes-comprehensive-review-on-brincidofovir-for-mpox-in-expert-review-of-anti-infective-therapy-journal

Emergent BioSolutions Inc. (NYSE:EBS) today announced the publication of a comprehensive review article, "Brincidofovir in ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION